- Home
- Companies
- bioMérieux S.A.
- Services
- Urgency of Early AKI Identification
Urgency of Early AKI Identification
A Key Advancement for Addressing a Dangerous Condition. The NephroCheck® Test was developed in response to the mounting personal and financial costs of acute kidney injury,1 along with the difficulty of assessing risk in the absence of signs and symptoms, as opposed to such conditions as myocardial infarction.2 The test is designed to meet the rising need for risk assessment.
Dr. V. Seenu Reddy, MD MBA, FACS, discusses the implications of NEPHROCHECK® Test [TIMP2 · IGFBP-7] to identify at-risk patients.
How can early identification of AKI affect patient outcomes?
Dr. Jeffery Vender examines how new biomarkers could benefit patients by identifying their risk for acute kidney injury earlier. AKI is often recognized late and can result in morbidity, mortality and increased cost of care.